GleamWall
中文EN

NMRA Neumora Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1885522 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY19.4%
TTM EPS YoY27.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-252.7%
ROA-139.6%
ROIC (approx.)-332.4%
Asset turnover—

Leverage & solvency

Liabilities / assets80.5%
Debt / equity6.11x
Current ratio4.08x
Interest coverage-34.16x

Cash quality & payout

Operating cash flow / net income0.88x
Accruals ratio-16.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$176.06M$200.93M
SG&A expense$60.09M$62.54M
Operating income-$241.16M-$263.46M
Interest expense$2.01M$0
Pretax income-$236.80M-$243.61M
Income tax$130,000$178,000
Net income-$236.93M-$243.79M
EBITDA-$240.95M-$262.83M
EPS (basic)-1.45-1.53
EPS (diluted)-1.45-1.53
Weighted avg. shares (diluted)163.39M159.38M
Balance sheet
Cash & equivalents$182.53M$142.15M
Short-term investments—$165.43M
Current assets$190.54M$314.06M
PP&E, net$40,000$1.14M
Total assets$191.05M$316.97M
Current liabilities$32.45M$29.89M
Short-term debt$60.00M—
Long-term debt$54.53M$0
Total debt$114.53M$0
Total liabilities$87.18M$29.91M
Shareholders' equity$103.87M$287.06M
Net debt-$68.00M-$142.15M
Shares outstanding174.26M161.71M
Cash flow statement
Operating cash flow-$206.44M-$182.94M
Investing cash flow$168.52M-$70.56M
Financing cash flow$77.09M$21.60M
Depreciation & amortization$208,000$631,000
Stock-based compensation$29.88M$39.99M

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.